Log in
E-mail
Password
Remember
Forgot password ?
Become a member for free
Sign up
Sign up
Settings
Settings
Dynamic quotes 
OFFON

4-Traders Homepage  >  Equities  >  Deutsche Boerse AG  >  Epigenomics AG    ECX   DE000A11QW50

SummaryQuotesChartsNewsAnalysisCalendarCompanyFinancialsConsensusRevisions 
News SummaryMost relevantAll newsSector newsTweets
The feature you requested does not exist. However, we suggest the following feature:

Epigenomics AG: Release according to Article 26, Section 1 of the WpHG [the German Securities Trading Act] with the objective of Europe-wide distribution

share with twitter share with LinkedIn share with facebook
share via e-mail
0
10/19/2017 | 02:00pm CEST

DGAP Voting Rights Announcement: Epigenomics AG
Epigenomics AG: Release according to Article 26, Section 1 of the WpHG [the German Securities Trading Act] with the objective of Europe-wide distribution

19.10.2017 / 13:54
Dissemination of a Voting Rights Announcement transmitted by DGAP - a service of EQS Group AG.
The issuer is solely responsible for the content of this announcement.


Notification of Major Holdings

1. Details of issuer
Epigenomics AG
Geneststraße 5
10829 Berlin
Germany

2. Reason for notification
  Acquisition/disposal of shares with voting rights
  Acquisition/disposal of instruments
X Change of breakdown of voting rights
  Other reason:

3. Details of person subject to the notification obligation
Name: City and country of registered office:
Mr Yong Yu,
Date of birth: 27 Feb 1961

4. Names of shareholder(s)
holding directly 3% or more voting rights, if different from 3.
Summit Hero Holding GmbH

5. Date on which threshold was crossed or reached:
06 Oct 2017

6. Total positions
  % of voting rights attached to shares
(total of 7.a.)
% of voting rights through instruments
(total of 7.b.1 + 7.b.2)
total of both in %
(7.a. + 7.b.)
total number of voting rights of issuer
Resulting situation 4.84 % 8.98 % 8.98 % 24014360
Previous notification 5.11 % 5.11 % 5.11 % /

7. Notified details of the resulting situation
a. Voting rights attached to shares (Sec.s 21, 22 WpHG)
ISIN absolute in %
  direct
(Sec. 21 WpHG)
indirect
(Sec. 22 WpHG)
direct
(Sec. 21 WpHG)
indirect
(Sec. 22 WpHG)
DE000A11QW50 0 1161139 0 % 4.84 %
Total 1161139 4.84 %

b.1. Instruments according to Sec. 25 para. 1 No. 1 WpHG
Type of instrument Expiration or maturity date Exercise or conversion period Voting rights absolute Voting rights in %
%
    Total %

b.2. Instruments according to Sec. 25 para. 1 No. 2 WpHG
Type of instrument Expiration or maturity date Exercise or conversion period Cash or physical settlement Voting rights absolute Voting rights in %
Obligation to rescind rollover Physical 1161139 4.84 %
Convertible bonds 31.12.2018 07.09.2017 until 31.12.2018 Physical 994397 4.14 %
      Total 2155536 8.98 %

8. Information in relation to the person subject to the notification obligation
  Person subject to the notification obligation is not controlled and does itself not control any other undertaking(s) holding directly or indirectly an interest in the (underlying) issuer (1.).
X Full chain of controlled undertakings starting with the ultimate controlling natural person or legal entity:

Name % of voting rights (if at least held 3% or more) % of voting rights through instruments (if at least held 5% or more) Total of both (if at least held 5% or more)
Yong Yu % % %
Cathay Fortune Corp. % % %
Cathay Fortune International Company Limited % % %
Eagle Noble Limited % % %
Mass Elite Limited % % %
Summit Hero Limited % % %
Summit Hero Holding GmbH 4.84 % % %

9. In case of proxy voting according to Sec. 22 para. 3 WpHG

Date of general meeting:
Holding position after general meeting: % (equals voting rights)

10. Other explanatory remarks:
No aggregation of voting rights attached to shares and instruments as voting rights attached to shares are also included in notified instruments. 



19.10.2017 The DGAP Distribution Services include Regulatory Announcements, Financial/Corporate News and Press Releases.
Archive at www.dgap.de


Language: English
Company: Epigenomics AG
Geneststraße 5
10829 Berlin
Germany
Internet: www.epigenomics.com

 
End of News DGAP News Service

620551  19.10.2017 

fncls.ssp?fn=show_t_gif&application_id=620551&application_name=news&site_id=zonebourse

© EQS 2017
share with twitter share with LinkedIn share with facebook
share via e-mail
0
Latest news on EPIGENOMICS AG
10/19 EPIGENOMICS AG : Release according to Article 26, Section 1 of the WpHG [the Ger..
10/16 EPIGENOMICS AG : Release according to Article 26, Section 1 of the WpHG [the Ger..
10/12 EPIGENOMICS AG : Release according to Article 26a of the WpHG [the German Securi..
09/20 EPIGENOMICS : issues new shares by way of private placement
09/20 EPIGENOMICS : issues new shares by way of private placement
09/08 EPIGENOMICS : issues convertible bonds
09/08 EPIGENOMICS : issues convertible bonds
09/07 EPIGENOMICS : Commences Post Approval Study on Epi proColon®
08/31 EPIGENOMICS : Colon cancer blood test post approval study begins
08/30 EPIGENOMICS : Commences Post Approval Study on Epi proColon®
More news
News from SeekingAlpha
08/12 Epigenomics' (EPGNF) CEO Gregory Hamilton on Q2 2017 Results - Earnings Call ..
08/09 Epigenomics reports Q2 results
05/10 Epigenomics reports Q1 results
05/01 Epigenomics' (EPGNF) CEO Gregory Hamilton on Q4 2016 Results - Earnings Call ..
04/27 Epigenomics Goes Private
Financials (€)
Sales 2017 3,15 M
EBIT 2017 -13,4 M
Net income 2017 -13,9 M
Finance 2017 35,5 M
Yield 2017 -
P/E ratio 2017 -
P/E ratio 2018
EV / Sales 2017 23,6x
EV / Sales 2018 4,70x
Capitalization 110 M
Chart EPIGENOMICS AG
Duration : Period :
Epigenomics AG Technical Analysis Chart | ECX | DE000A11QW50 | 4-Traders
Income Statement Evolution
Consensus
Sell
Buy
Mean consensus OUTPERFORM
Number of Analysts 2
Average target price 6,11 €
Spread / Average Target 35%
EPS Revisions
Managers
NameTitle
Gregory K. Hamilton Chief Executive Officer
Heino von Prondzynski Chairman-Supervisory Board
Uwe Staub Chief Operating Officer
Günther Reiter Vice Chairman-Supervisory Board
Ann Clare Kessler Member-Supervisory Board
Sector and Competitors
1st jan.Capitalization (M$)
EPIGENOMICS AG2.60%131
MIRACA HOLDINGS INC.0.76%2 631
GENSCRIPT BIOTECH CORP164.59%2 269
BEIJING STRONG BIOTECHNOLOGIES INC--.--%1 178
INNATE PHARMA-29.50%697
SEEGENE INC--.--%637